0629 GMT - News that Vaxcyte's experimental pneumonia vaccine held up against two approved shots in a late-stage clinical trial should open a new revenue stream for Switzerland's Lonza Group starting in a couple of years, RBC Capital Markets' Charles Weston says in a research note. "Lonza is fully embedded in Vaxcyte's manufacturing supply chain through multiple overlapping agreements," the analyst says. Vaxcyte's vaccine is projected to reach $4 billion in annual peak sales, though it is unlikely to launch before 2028, RBC says. At its peak, this could translate into $400 million to $550 million in revenue for Lonza, the analyst estimates.